Korro Bio, Inc. (KRRO) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $14.00K; Additional Paid in CapitalUSD $525.79M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-189.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $14.00K; Additional Paid in CapitalUSD $523.09M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in CapitalUSD $435.06M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $212.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in CapitalUSD $432.61M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $214.00K.
Korro Bio, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $14.00K | $525.79M | $-189.00K | $-422.39M | $103.23M | 3 month · $2.70M | (m) |
| 2026-03-31 | $0.00 | $14.00K | $523.09M | $5.00K | $-403.47M | $119.63M | 3 month · $2.73M | (m) |
| 2025-12-31 | $0.00 | $9.00K | $435.06M | $212.00K | $-383.85M | $51.44M | 12 month · $7.66M | (m) |
| 2025-09-30 | $0.00 | $9.00K | $432.61M | $214.00K | $-333.80M | $99.03M | 3 month · $1.82M | (m) |
| 2025-06-30 | $0.00 | $9.00K | $430.66M | $177.00K | $-315.74M | $115.10M | 3 month · $2.00M | (m) |
| 2025-03-31 | $0.00 | $9.00K | $428.66M | $264.00K | $-289.97M | $138.96M | 3 month · $1.76M | (m) |
| 2024-12-31 | $0.00 | $9.00K | $426.72M | $268.00K | $-266.59M | $160.41M | 12 month · $4.46M | (m) |
| 2024-09-30 | $0.00 | $9.00K | $424.44M | $574.00K | $-245.39M | $179.63M | 3 month · $1.27M | (m) |
| 2024-06-30 | $0.00 | $9.00K | $422.44M | $21.00K | $-224.39M | $198.08M | 3 month · $967.00K | (m) |
| 2024-03-31 | $0.00 | $8.00K | $353.91M | (m) | $-202.56M | $151.36M | 3 month · $865.00K | (m) |
| 2023-12-31 | $0.00 | $8.00K | $352.91M | $0.00 | $-183.00M | $169.91M | 12 month · $2.38M | (m) |
| 2023-09-30 | $0.00 | $37.00K | $340.31M | $10.00K | $-303.62M | $-153.26M | 3 month · $404.00K 9 month · $9.25M | (m) |
| 2023-06-30 | $0.00 | $36.00K | $337.38M | $-6.00K | $-292.00M | $-135.40M | 3 month · $401.00K 6 month · $6.33M | (m) |
| 2023-03-31 | $0.00 | $36.00K | $334.49M | $-64.00K | $-281.21M | $-118.23M | 3 month · $343.00K | (m) |
| 2022-12-31 | $0.00 | $0.00 | $2.81M | $-5.00K | $-101.83M | $-99.03M | 12 month · $1.13M | (m) |
| 2022-09-30 | $0.00 | $35.00K | $326.62M | $-376.00K | $-244.30M | $81.97M | 3 month · $5.59M 9 month · $15.43M | (m) |
| 2022-06-30 | $0.00 | $35.00K | $320.97M | $-392.00K | $-224.76M | $95.85M | 3 month · $4.56M 6 month · $9.83M | (m) |
| 2022-03-31 | $0.00 | $35.00K | $316.40M | $-296.00K | $-203.47M | $112.67M | 3 month · $5.27M | (m) |
| 2021-12-31 | $0.00 | $35.00K | $310.94M | $-62.00K | $-180.09M | $-42.21M | 12 month · $21.75M | (m) |
| 2021-09-30 | (m) | $35.00K | $305.66M | $3.00K | $-158.59M | $147.12M | 3 month · $5.89M 9 month · $16.59M | (m) |
| 2021-06-30 | (m) | $34.00K | $299.43M | $7.00K | $-133.43M | $166.04M | 3 month · $6.09M 6 month · $10.70M | (m) |
| 2021-03-31 | (m) | $34.00K | $293.14M | $10.00K | $-115.77M | $177.41M | 3 month · $4.61M | (m) |
| 2020-12-31 | $0.00 | $34.00K | $287.83M | $27.00K | $-95.40M | $192.49M | 12 month · $9.98M | (m) |
| 2020-09-30 | (m) | $34.00K | $284.68M | $44.00K | $-85.17M | $199.59M | 3 month · $2.64M 9 month · $7.22M | (m) |
| 2020-06-30 | (m) | $31.00K | $241.44M | $60.00K | $-79.83M | $161.70M | 3 month · $2.41M 6 month · $4.58M | (m) |
| 2020-03-31 | (m) | $31.00K | $238.63M | $-15.00K | $-73.80M | $164.85M | 3 month · $2.16M | (m) |
| 2019-12-31 | (m) | $31.00K | $236.16M | $54.00K | $-68.89M | $167.36M | 12 month · $3.61M | $236.16M |
| 2019-09-30 | (m) | $2.00K | (m) | $116.00K | $-63.35M | $-59.65M | 3 month · $925.00K 9 month · $2.46M | $3.58M |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-59.12M | 3 month · $1.48M 6 month · $1.53M | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-53.91M | 3 month · $49.00K | (m) |
| 2018-12-31 | (m) | $2.00K | (m) | (m) | $-49.09M | $-48.28M | 12 month · $455.00K | $804.00K |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $-43.03M | 3 month · $102.00K 9 month · $267.00K | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $-38.02M | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-29.64M | 12 month · $91.00K | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $-9.66M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |